摘要
Abstract
Objective To observe the clinical effect of arsenic trioxide and low dose of the treatment of high risk patients with high risk of bone marrow hyperplasia in elderly patients. Methods Choice over the age of 60 high risk myeloid hyperplasia abnormal syndrome patients 25 cases MDS-RAEB-1 type in 12 cases, MDS-RAEB-2 type in 8 cases, were divided for 2 groups. Group 1 received intravenous arsenic trioxide, group 1 given low dose cytarabine intravenous drip, respectively in 7 days, 14 days, 21 days ,28 days observed changes in blood and in 28 days examined the bone marrow. Result Blood of 8 cases were sig-nificantly improved after the end of the treatment of arsenic trioxide treatment, 3 cases no improvement, examined the bone mar-row, 7 cases achieved complete remission, 3 cases of partial remission, primitive cells significantly decreased the proportion, treatment process was well tolerated;cytarabine treatment group 6 cases improve the hemogram, review of bone marrow, 3 cases a-chieved complete remission, 4cases of partial remission, 5 patients had no response, two groups of patients had no serious adverse reactions and complications. Conclusion Arsenic trioxide induced chemotherapy in the treatment of elderly patients with high risk of bone marrow hyperplasia syndrome compared with the traditional low dose of the high dose of the remission rate of remission rate, patients with good tolerance, low cost of treatment, it is worth clinical promotion关键词
三氧化二砷/阿糖胞苷/老年,高危,骨髓增生异常综合征Key words
arsenic trioxide/A sugar/old age/high-risk/Bone marrow hyperplasia syndrome分类
医药卫生
